KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Non-Current Deffered Revenue: 2017-2018

Historic Non-Current Deffered Revenue for Neogenomics (NEO) over the last 1 years, with Dec 2018 value amounting to $927,000.

  • Neogenomics' Non-Current Deffered Revenue rose 227.56% to $927,000 in Q4 2018 from the same period last year, while for Dec 2018 it was $927,000, marking a year-over-year increase of 227.56%. This contributed to the annual value of $927,000 for FY2018, which is 227.56% up from last year.
  • Per Neogenomics' latest filing, its Non-Current Deffered Revenue stood at $927,000 for Q4 2018, which was down 22.69% from $1.2 million recorded in Q3 2018.
  • In the past 5 years, Neogenomics' Non-Current Deffered Revenue registered a high of $1.2 million during Q3 2018, and its lowest value of $283,000 during Q4 2017.
  • In the last 2 years, Neogenomics' Non-Current Deffered Revenue had a median value of $648,000 in 2018 and averaged $715,800.
  • Data for Neogenomics' Non-Current Deffered Revenue shows a peak YoY surged of 227.56% (in 2018) over the last 5 years.
  • Neogenomics' Non-Current Deffered Revenue (Quarterly) stood at $283,000 in 2017, then soared by 227.56% to $927,000 in 2018.
  • Its Non-Current Deffered Revenue was $927,000 in Q4 2018, compared to $1.2 million in Q3 2018 and $648,000 in Q2 2018.